Carmot Therapeutics Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
70
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$3.3B
Carmot Therapeutics General Information
Description
Carmot Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes. It has three clinical-stage product candidates are: CT-388, a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of obesity and type 2 diabetes (T2D); CT-996, a once-daily oral, small molecule GLP-1 receptor agonist for the treatment of obesity and T2D; and CT-868, a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist for the treatment of type 1 diabetes (T1D) patients with overweight or obesity.
Contact Information
Website
www.carmot.us(Operating Subsidiary)
Corporate Office
- 740 Heinz Avenue
- Berkeley, CA 94710
- United States
Corporate Office
- 740 Heinz Avenue
- Berkeley, CA 94710
- United States
Carmot Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Merger/Acquisition | 26-Jan-2024 | $3.3B | Completed | Clinical Trials - Phase 2 | ||
| 10. IPO | 17-Nov-2023 | Cancelled | Clinical Trials - Phase 2 | |||
| 9. Later Stage VC (Series E) | 25-May-2023 | Completed | Clinical Trials - Phase 2 | |||
| 8. Later Stage VC (Series D) | 25-Jul-2022 | Completed | Clinical Trials - Phase 2 | |||
| 7. Later Stage VC (Series C) | 30-Sep-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Debt - PPP | 03-May-2020 | Completed | Clinical Trials - Phase 2 | |||
| 5. Later Stage VC (Series B) | 17-Jan-2018 | Completed | Pre-Clinical Trials | |||
| 4. Early Stage VC (Series A) | 17-Jul-2012 | Completed | Startup | |||
| 3. Grant | 08-Dec-2011 | $300K | $300K | Completed | Startup | |
| 2. Grant | 31-Dec-2010 | $440K | $300K | Completed | Startup |
Carmot Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series E | ||||||||
| Series D1 | ||||||||
| Series D | ||||||||
| Series C | ||||||||
| Series B | 1,977,878 | $0.001000 | $0.51 | $6.37 | $6.37 | 1x | $6.37 | 3.64% |
| Series A | 3,431,745 | $0.001000 | $0.05 | $0.63 | $0.63 | 1x | $0.63 | 6.32% |
Carmot Therapeutics Comparisons
Industry
Financing
Details
Carmot Therapeutics Competitors (1)
One of Carmot Therapeutics’s competitors is Gelesis, a Formerly VC-backed company based in Calimera, Italy.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gelesis | Formerly VC-backed | Calimera, Italy |
Carmot Therapeutics Patents
Carmot Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026213480-A1 | Gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use | Pending | 04-Apr-2025 | ||
| US-20260137758-A1 | Treatment of steatotic liver disease associated with metabolic dysfunction | Pending | 20-Nov-2024 | ||
| WO-2026112366-A1 | Treatment of steatotic liver disease associated with metabolic dysfunction | Pending | 20-Nov-2024 | ||
| WO-2026112366-A9 | Treatment of steatotic liver disease associated with metabolic dysfunction | Pending | 20-Nov-2024 | ||
| WO-2026073030-A1 | Combination therapy of peptide tyrosine-tyrosine (pyy) analogues and glp-1r agonists | Pending | 27-Sep-2024 | A61K38/26 |
Carmot Therapeutics Signals
Carmot Therapeutics Former Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| 5AM Ventures | Venture Capital | Minority | ||
| Amgen | Corporation | Minority | ||
| Deep Track Capital | Venture Capital | Minority | ||
| Franklin Templeton | Asset Manager | Minority | ||
| Frazier Healthcare Partners | PE/Buyout | Minority |
Carmot Therapeutics FAQs
-
When was Carmot Therapeutics founded?
Carmot Therapeutics was founded in 2008.
-
Where is Carmot Therapeutics headquartered?
Carmot Therapeutics is headquartered in Berkeley, CA.
-
What is the size of Carmot Therapeutics?
Carmot Therapeutics has 70 total employees.
-
What industry is Carmot Therapeutics in?
Carmot Therapeutics’s primary industry is Biotechnology.
-
Is Carmot Therapeutics a private or public company?
Carmot Therapeutics is a Private company.
-
What is the current valuation of Carmot Therapeutics?
The current valuation of Carmot Therapeutics is .
-
What is Carmot Therapeutics’s current revenue?
The current revenue for Carmot Therapeutics is .
-
How much funding has Carmot Therapeutics raised over time?
Carmot Therapeutics has raised $374M.
-
Who are Carmot Therapeutics’s investors?
5AM Ventures, Amgen, Deep Track Capital, Franklin Templeton, and Frazier Healthcare Partners are 5 of 19 investors who have invested in Carmot Therapeutics.
-
Who are Carmot Therapeutics’s competitors?
Gelesis is a competitor of Carmot Therapeutics.
-
When was Carmot Therapeutics acquired?
Carmot Therapeutics was acquired on 26-Jan-2024.
-
Who acquired Carmot Therapeutics?
Carmot Therapeutics was acquired by Roche.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process